Stocklytics Platform
Asset logo for symbol PCRX
Pacira BioSciences
PCRX50
$25.71arrow_drop_down1.40%-$0.36
Asset logo for symbol PCRX
PCRX50

$25.71

arrow_drop_down1.40%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Pacira BioSciences (PCRX) Stocklytics Forecast

Pacira BioSciences Inc (PCRX) is a biopharmaceutical company that specializes in developing and commercializing innovative products for the acute care market. The company is focused on providing non-opioid pain management options to help reduce the need for opioids and improve patient outcomes. With a strong pipeline of products and a commitment to research and development, Pacira BioSciences is well-positioned for future growth.
When it comes to predicting the stock price of Pacira BioSciences Inc (PCRX), there are a few factors to consider. AI and machine learning algorithms can analyze historical data, market trends, and other relevant information to generate forecasts. While these predictions can provide valuable insights, it's important to remember that they are not guaranteed and should be used as one tool among many when making investment decisions.
add Pacira BioSciences  to watchlist

Keep an eye on Pacira BioSciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Pacira BioSciences (PCRX) stock?

Analysts have set a target price of $60.57 for Pacira BioSciences (PCRX), based on forecasts from 28 analysts. The predicted price range extends from a high of $76 to a low of $42. This represents a potential increase of up to 195.55% and a decrease of 63.33% from the current price of $25.71. These forecasts are as of 2022 Nov 03.
help

What are the analyst ratings for Pacira BioSciences (PCRX) stock?

The analyst ratings for Pacira BioSciences (PCRX) are distributed as follows: 4 analysts recommend buying, 2 have a neutral stance, and 1 suggest selling. The prevailing sentiment among the total of 7 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Pacira BioSciences .
help

What is the AI price prediction for Pacira BioSciences (PCRX) stock?

At present, there is no AI or machine-learning-based price prediction available for Pacira BioSciences (PCRX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level